- Home
- IONS vs SLGN Comparison
IONS vs SLGN Comparison
Compare IONS & SLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- SLGN
- Stock Information
- Founded
- IONS 1989
- SLGN 1987
- Country
- IONS United States
- SLGN United States
- Employees
- IONS N/A
- SLGN N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- SLGN Containers/Packaging
- Sector
- IONS Health Care
- SLGN Industrials
- Exchange
- IONS Nasdaq
- SLGN Nasdaq
- Market Cap
- IONS 5.4B
- SLGN 5.2B
- IPO Year
- IONS 1991
- SLGN 1997
- Fundamental
- Price
- IONS $33.51
- SLGN $55.08
- Analyst Decision
- IONS Buy
- SLGN Strong Buy
- Analyst Count
- IONS 18
- SLGN 9
- Target Price
- IONS $57.41
- SLGN $63.11
- AVG Volume (30 Days)
- IONS 1.5M
- SLGN 594.7K
- Earning Date
- IONS 04-30-2025
- SLGN 04-30-2025
- Dividend Yield
- IONS N/A
- SLGN 1.45%
- EPS Growth
- IONS N/A
- SLGN N/A
- EPS
- IONS N/A
- SLGN 2.69
- Revenue
- IONS $717,253,000.00
- SLGN $6,004,317,000.00
- Revenue This Year
- IONS $7.14
- SLGN $12.29
- Revenue Next Year
- IONS $18.89
- SLGN $2.69
- P/E Ratio
- IONS N/A
- SLGN $20.47
- Revenue Growth
- IONS N/A
- SLGN 1.99
- 52 Week Low
- IONS $23.95
- SLGN $41.14
- 52 Week High
- IONS $52.34
- SLGN $58.14
- Technical
- Relative Strength Index (RSI)
- IONS 56.80
- SLGN 57.66
- Support Level
- IONS $32.00
- SLGN $54.16
- Resistance Level
- IONS $33.65
- SLGN $55.83
- Average True Range (ATR)
- IONS 1.08
- SLGN 0.82
- MACD
- IONS -0.10
- SLGN -0.14
- Stochastic Oscillator
- IONS 55.72
- SLGN 49.78
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About SLGN Silgan Holdings Inc.
Silgan Holdings manufactures about half of the metal food containers in North America. Its major customers include Campbell Soup, Nestle, and Del Monte. Silgan's other business segments include plastic dispensers and containers for personal and healthcare products and a closures business that manufactures metal and plastic lids and caps.